GLP-1 and MS: What UK Patients Should Know (October 2026)

01 · The core answer

Can you take GLP-1 medicines if you have MS?

It depends on your individual health, and the decision should involve the clinicians who know your MS.

Every order starts with a free online consultation, and a GPhC-registered prescriber reviews your answers. Mention your MS, your current medicines and any recent relapses or changes. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

02 · Weight versus research

Two different questions: weight and MS research

The first question is whether a GLP-1 or GIP/GLP-1 medicine can help you manage weight. That is what Mounjaro is licensed for, and the trial evidence relates to that use only.¹

The second is whether these medicines could change the course of MS itself. That is a research question. Studies are ongoing, and nobody should buy a weight-loss injection hoping it will treat MS. If you want to understand where the research stands, ask your neurology team, who can point you to current trials.

If you are weighing up your options, our guides on Mounjaro and MS and taking Mounjaro if you have MS go through the practical points in more detail. When you are ready to look at treatment, the Mounjaro pen page has live prices and the consultation.

Related guide: Rowe glp1.

03 · What Mounjaro is

What Mounjaro is and what it is licensed for

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹ It comes as a pre-filled multi-dose pen (KwikPen) in strengths from 2.5mg to 15mg.¹³

Multiple sclerosis is not a licensed use. That matters because licensed uses are the ones where safety and effectiveness have been formally assessed, and the product information is written around them.

It is used alongside a reduced-calorie diet and increased physical activity. It is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber.

04 · How it works

How tirzepatide works

Tirzepatide activates two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹

In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. This dual action distinguishes it from single-action GLP-1 medicines such as semaglutide (Wegovy and Ozempic).

You may read that GLP-1 receptors are also found in the brain. That is a research observation, and it does not tell you what a weight-management dose will do for MS.

05 · What the trials show

What the weight-loss trials show

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.²

These are trial averages. Individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. The trial was not designed around people with MS, so it cannot tell you how the medicine behaves in your situation.

If MS limits how much you can move, tell your prescriber. Activity levels are part of a realistic plan, and your care team can help you set sensible expectations.

06 · Talking to your specialists

Who to speak to before you start

Start with your neurologist or MS nurse, and your GP. They know your disease course, your disease-modifying treatment and your other medicines. Ask whether starting a weight-loss injection fits your current plan, and what to watch for.

Tell the prescriber reviewing your consultation about every medicine you take. If you start treatment and notice a new symptom, tell your prescriber or MS team rather than assuming it is, or is not, related to the injection. For severe, persistent stomach pain, chest pain, fainting, swelling of the face, lips, tongue or throat, difficulty breathing, or yellowing of the skin or eyes, get medical help straight away. You can also report suspected side effects through the MHRA Yellow Card scheme.¹⁹

07 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

08 · NHS or private

NHS access or private treatment

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first.⁴⁶

Your GP or MS team can tell you whether you are likely to qualify locally. If you choose regulated private treatment instead, our weight loss clinic explains how the consultation works. For comparison across the wider topic, see MS and weight loss drugs.